John McHutchison, Assembly Biosciences CEO (Getty Images)

As­sem­bly Bio's he­pati­tis B pro­gram flops as a po­ten­tial cure in PhII, send­ing shares spi­ral­ing

Look­ing for a he­pati­tis B cure, As­sem­bly Bio­sciences $ASMB has struck out in a Phase II.

The South San Fran­cis­co-based com­pa­ny an­nounced Thurs­day af­ter­noon that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.